CWM
CRSP icon

Cornerstone Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Cornerstone Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,396
Closed -$220K – 697
2025
Q3 		$220K Buy
+3,396
New +$195K 0.01% 618

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GP
GSK plc London $599M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cornerstone Wealth Management's CRSP Position: Q4 2025 in Review

Cornerstone Wealth Management sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 3,396 shares — an estimated $220K sold.

Cornerstone Wealth Management first reported a position in CRSP in Q3 2025 and held it in 1 quarter. The position peaked at $220K in Q3 2025. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

  • Cornerstone Wealth Management reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Cornerstone Wealth Management sold 3,396 CRISPR Therapeutics shares in Q4 2025, an estimated $220K.
  • Cornerstone Wealth Management first reported a position in CRISPR Therapeutics in Q3 2025 and held it in 1 quarter.
  • Cornerstone Wealth Management's CRISPR Therapeutics position peaked at $220K in Q3 2025.
  • 479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Cornerstone Wealth Management's 13F filing for Q4 2025, filed 5 Feb 2026.